Diagnostics for severe sepsis and community acquired pneumonia (CAPSOD) capsod

This NIAID-funded program, titled "CAPSOD", is a public-private, multidisciplinary collaboration involving investigators at ten organizations: NCGR; Duke University Medical Center, Durham, N.C.; Henry Ford Hospital, Detroit, MI; Durham Veterans Administration Medical Center, Durham, NC; Eli Lilly and Co., Indianapolis, IN; Monarch Life Sciences, Indianapolis, IN; Pfizer, Inc., Groton, CT; Metabolon, Inc., Durham, NC; Roche Diagnostics Corp., Indianapolis, IN; and ProSanos Corp., La Jolla, Calif. CAPSOD is a five-year program that will prospectively enroll patients with sepsis and CAP at Duke University Medical Center and Henry Ford Hospital. The study will use advanced bioinformatic and proteomic technologies to identify specific protein changes, or biomarkers, in patient blood samples that predict outcome in sepsis and CAP. Development of biomarker-based tests will permit patient selection for appropriate disposition, such as the intensive care unit, and use of intensive medical therapies, thereby reducing mortality and increasing effectiveness of resource allocation. See the full CAPSOD description at ClinicialTrials.gov.